XM does not provide services to residents of the United States of America.
G
G

Getinge

News

FDA Highlights Safety Concerns & Class I Recall for Getinge's Vasoview Hemopro Devices

BRIEF-FDA Highlights Safety Concerns & Class I Recall for Getinge's Vasoview Hemopro Devices Nov 15 (Reuters) - FDA: FDA: ALERTING HEALTH CARE PROVIDERS ABOUT SAFETY CONCERNS WITH GETINGE/MAQUET VASOVIEW HEMOPRO EVH SYSTEMS AND SUPPLY CONCERN FOR EVH DEVICES- WEBSITE FDA: WORKING WITH MANUFACTURER TO EVALUATE REPORTS OF SILICONE DETACHMENT WITH VAS
G

Barratt Redrow, Genuit Group, Munich Re

EUROPE RESEARCH ROUNDUP-Barratt Redrow, Genuit Group, Munich Re Oct 21 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Barratt Redrow, Genuit Group and Munich Re, on Monday. HIGHLIGHTS * Barratt Redrow Plc BTRW.L : Morgan Stanley raises to overweight from equal-weight * Genuit Group Plc GENG.L : JP Morgan initiates coverage with neutral rating; PT 535p * Intertek ITRK.L : RBC cuts to sector perform from outperform * Munich Re MUVGn.
B
B
B
B
B
C
D
D
E
E
E
F
G
N
O
R
S
A
P

Europe's STOXX 600 ends week higher as tech stocks rebound

UPDATE 2-Europe's STOXX 600 ends week higher as tech stocks rebound For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Luxury stocks aid gains on France's CAC 40 Elisa slumps on unexpected Q3 revenue fall Goldman Sachs slashes STOXX 600 2024 earnings growth forecast STOXX 600 up 0.2% Updated at 1602 GMT By Paolo Laudani, Ankika Biswas and Johann M Cherian Oct 18 (Reuters) - Europe's STOXX 600 ended higher on Friday, as tech stocks made a s
B
D
G
G
H
I
K
L
R
V
A
S
E
F
G

Europe before the bell: A calmer end to the week

LIVE MARKETS-Europe before the bell: A calmer end to the week Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com EUROPE BEFORE THE BELL: A CALMER END TO THE WEEK European stocks are in for a tepid end to the week, as traders ramp up bets on more ECB rate cuts after Thursday's and digest some less than stellar data out of China.
G
N
V
E
F
U
G

Getinge Keeps 2024 Outlook Unchanged

BRIEF-Getinge Keeps 2024 Outlook Unchanged Oct 18 (Reuters) - Getinge AB GETIb.ST : TEMPORARY DELIVERY DISRUPTIONS HAD A NEGATIVE IMPACT ON EARNINGS BIO-PROCESSING WITH DOUBLE-DIGIT GROWTH IN ORGANIC ORDER INTAKE BOTH IN US AND IN CHINA IN Q3 OUTLOOK 2024: NET SALES FOR 2024 ARE EXPECTED TO INCREASE BY 2–5% ORGANICALLY (UNCHANGED) ORGANIC SALES F
G

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.